Skip to Content

Generic Nocdurna Availability

Last updated on July 7, 2021.

Nocdurna is a brand name of desmopressin, approved by the FDA in the following formulation(s):

NOCDURNA (desmopressin acetate - tablet;sublingual)

  • Manufacturer: FERRING PHARMS INC
    Approval date: June 21, 2018
    Strength(s): 0.0277MG [RLD], 0.0553MG [RLD]

Has a generic version of Nocdurna been approved?

No. There is currently no therapeutically equivalent version of Nocdurna available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nocdurna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods comprising desmopressin
    Patent 10,137,167
    Issued: November 27, 2018
    Assignee(s): Ferring B.V.

    The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.

    Patent expiration dates:

    • May 21, 2029
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
  • Pharmaceutical formulations of desmopressin
    Patent 10,307,459
    Issued: June 4, 2019
    Assignee(s): FERRING B.V.

    Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

    Patent expiration dates:

    • May 7, 2023
      ✓ 
      Drug product
  • Patent 11,020,448

    Patent expiration dates:

    • May 21, 2029
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
  • Orodispersible dosage forms of desmopressin acetate
    Patent 7,560,429
    Issued: July 14, 2009
    Inventor(s): Nilsson; Anders & Lindner; Hans & Wittendorff; Jørgen
    Assignee(s): Ferring B.V.

    Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

    Patent expiration dates:

    • February 2, 2024
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
      ✓ 
      Drug product
  • Pharmaceutical formulations
    Patent 7,947,654
    Issued: May 24, 2011
    Inventor(s): Nilsson; Anders & Lindner; Hans & Wittendorff; Jørgen
    Assignee(s): Ferring B.V.

    Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

    Patent expiration dates:

    • December 29, 2023
      ✓ 
      Drug product
  • Methods of treatment using orodispersible desmopressin pharmaceutical formulations
    Patent 8,802,624
    Issued: August 12, 2014
    Assignee(s): Ferring B.V.

    Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 μg.

    Patent expiration dates:

    • December 29, 2023
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
  • Methods using desmopressin acetate in orodispersible form
    Patent 9,220,747
    Issued: December 29, 2015
    Assignee(s): FERRING B.V.

    Described are orodispersible solid dosage forms of desmopressin or a pharmaceutically acceptable salt thereof useful for treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus. The dosage forms disintegrate in the mouth within 10 seconds and provide good desmopressin bioavailability.

    Patent expiration dates:

    • May 7, 2023
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
  • Pharmaceutical formulations of desmopressin
    Patent 9,504,647
    Issued: November 29, 2016
    Assignee(s): FERRING B.V.

    Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

    Patent expiration dates:

    • May 7, 2023
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
      ✓ 
      Drug product
  • Pharmaceutical formulations of desmopressin
    Patent 9,919,025
    Issued: March 20, 2018
    Assignee(s): FERRING B.V.

    Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.

    Patent expiration dates:

    • May 7, 2023
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
  • Methods comprising desmopressin
    Patent 9,974,826
    Issued: May 22, 2018
    Assignee(s): Ferring B.V.

    The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.

    Patent expiration dates:

    • April 13, 2030
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
    • April 13, 2030
      ✓ 
      Patent use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • June 21, 2021 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.